News >

Trastuzumab Deruxtecan Approved in Japan for HER2+ Metastatic Breast Cancer

Jason M. Broderick @jasoncology
Published: Wednesday, Mar 25, 2020

breast cancer
The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved trastuzumab deruxtecan (Enhertu) for the treatment of patients with HER2-positive unresectable or recurrent breast cancer who have had prior chemotherapy and are refractory or intolerant to standard treatments.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication